Nonsense-mediated decay in genetic disease: friend or foe?

[1]  F. Brito.  Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases , 2014 .

[2]  A. Drack,et al.  A Novel c.1135_1138delCTGT Mutation in CLN3 Leads to Juvenile Neuronal Ceroid Lipofuscinosis , 2013, Journal of child neurology.

[3]  D. Pearce,et al.  A Novel c.776_777insA Mutation in CLN1 Leads to Infantile Neuronal Ceroid Lipofuscinosis , 2013, Journal of child neurology.

[4]  D. Pearce,et al.  The role of nonsense-mediated decay in neuronal ceroid lipofuscinosis. , 2013, Human molecular genetics.

[5]  J. Rosenfeld,et al.  Contribution of copy number variants involving nonsense-mediated mRNA decay pathway genes to neuro-developmental disorders. , 2013, Human molecular genetics.

[6]  D. Bedwell,et al.  Attenuation of Nonsense-Mediated mRNA Decay Enhances In Vivo Nonsense Suppression , 2013, PloS one.

[7]  A. Goris,et al.  Novel COL4A1 mutations cause cerebral small vessel disease by haploinsufficiency. , 2013, Human molecular genetics.

[8]  M. Wilkinson,et al.  Regulation of nonsense‐mediated mRNA decay , 2012, Wiley interdisciplinary reviews. RNA.

[9]  J. Dougherty,et al.  Pharmaceutical therapies to recode nonsense mutations in inherited diseases. , 2012, Pharmacology & therapeutics.

[10]  Allan Jacobson,et al.  NMD: a multifaceted response to premature translational termination , 2012, Nature Reviews Molecular Cell Biology.

[11]  M. Jung,et al.  Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. , 2012, Human molecular genetics.

[12]  D. Bedwell,et al.  Suppression of premature termination codons as a therapeutic approach , 2012, Critical reviews in biochemistry and molecular biology.

[13]  E. Grzybowska,et al.  Human intronless genes: functional groups, associated diseases, evolution, and mRNA processing in absence of splicing. , 2012, Biochemical and biophysical research communications.

[14]  Anders Krogh,et al.  Mammalian tissues defective in nonsense-mediated mRNA decay display highly aberrant splicing patterns , 2012, Genome Biology.

[15]  L. Maquat,et al.  Regulation of cytoplasmic mRNA decay , 2012, Nature Reviews Genetics.

[16]  T. Visser,et al.  Growth hormone insensitivity syndrome caused by a heterozygous GHR mutation: phenotypic variability owing to moderation by nonsense‐mediated decay , 2012, Clinical endocrinology.

[17]  J. Hebebrand,et al.  Rescue of Melanocortin 4 Receptor (MC4R) Nonsense Mutations by Aminoglycoside‐Mediated Read‐Through , 2012, Obesity.

[18]  L. Maquat,et al.  Regulation of cytoplasmic mRNA decay , 2012, Nature Reviews Genetics.

[19]  Vidya Balagopal,et al.  Ways and means of eukaryotic mRNA decay. , 2012, Biochimica et biophysica acta.

[20]  T. Morio,et al.  Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia‐telangiectasia , 2012, Human mutation.

[21]  M. Okoniewski,et al.  Autoregulation of the nonsense-mediated mRNA decay pathway in human cells. , 2011, RNA.

[22]  D. Rosskopf,et al.  Aminoglycoside-induced suppression of CYP2C19*3 premature stop codon , 2011, Pharmacogenetics and genomics.

[23]  A. Mukherjee,et al.  Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. , 2011, Molecular genetics and metabolism.

[24]  D. Bedwell,et al.  Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases , 2011, Wiley interdisciplinary reviews. RNA.

[25]  F. Hirahara,et al.  N- and C-terminal Upf1 phosphorylations create binding platforms for SMG-6 and SMG-5:SMG-7 during NMD , 2011, Nucleic acids research.

[26]  E. Stone,et al.  RNA homeostasis governed by cell type-specific and branched feedback loops acting on NMD. , 2011, Molecular cell.

[27]  L. Maquat,et al.  Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: to die or not to die, that is the question. , 2011, Current opinion in genetics & development.

[28]  Z. Bebők,et al.  Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54 , 2011, Journal of Molecular Medicine.

[29]  N. Amariglio,et al.  Ex Vivo Treatment with a Novel Synthetic Aminoglycoside NB54 in Primary Fibroblasts from Rett Syndrome Patients Suppresses MECP2 Nonsense Mutations , 2011, PloS one.

[30]  H. Dietz,et al.  Perturbation of thymocyte development in nonsense-mediated decay (NMD)-deficient mice , 2011, Proceedings of the National Academy of Sciences.

[31]  Rachid Karam,et al.  Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. , 2011, Molecular cell.

[32]  J. Hacia,et al.  Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations , 2011, Journal of cellular biochemistry.

[33]  Jung-Eun Park,et al.  Altered microRNA regulation in Huntington's disease models , 2011, Experimental Neurology.

[34]  M. Bennett,et al.  PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation , 2011, Journal of Inherited Metabolic Disease.

[35]  U. Wolfrum,et al.  PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C. , 2011, Human gene therapy.

[36]  J. Lykke-Andersen,et al.  Upf1 ATPase-Dependent mRNP Disassembly Is Required for Completion of Nonsense- Mediated mRNA Decay , 2010, Cell.

[37]  P. Huppke,et al.  Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model , 2010, Journal of Molecular Medicine.

[38]  F. Vermeulen,et al.  Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. , 2010, American journal of respiratory and critical care medicine.

[39]  J. Eubanks,et al.  Aminoglycoside‐mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro , 2010, Journal of neuroscience research.

[40]  L. Maquat,et al.  UPF1 association with the cap-binding protein, CBP80, promotes nonsense-mediated mRNA decay at two distinct steps. , 2010, Molecular cell.

[41]  L. Maquat,et al.  The Pioneer Round of Translation: Features and Functions , 2010, Cell.

[42]  C. Seoighe,et al.  Heritability in the Efficiency of Nonsense-Mediated mRNA Decay in Humans , 2010, PloS one.

[43]  J. Mendell,et al.  Gentamicin‐induced readthrough of stop codons in duchenne muscular dystrophy , 2010, Annals of neurology.

[44]  V. Belakhov,et al.  Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. , 2010, Bioorganic & medicinal chemistry.

[45]  Yoon Ki Kim,et al.  Nonsense‐mediated translational repression involves exon junction complex downstream of premature translation termination codon , 2010, FEBS letters.

[46]  Rosa Bartolomeo,et al.  Mucopolysaccharidosis , 2009, Radiopaedia.org.

[47]  R. Damoiseaux,et al.  Nonaminoglycoside compounds induce readthrough of nonsense mutations , 2009, The Journal of experimental medicine.

[48]  H. Peters,et al.  Stop codon read-through of a methylmalonic aciduria mutation. , 2009, Molecular genetics and metabolism.

[49]  J. Gécz,et al.  A UPF3-mediated regulatory switch that maintains RNA surveillance , 2009, Nature Structural &Molecular Biology.

[50]  J. Schacht,et al.  Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. , 2009, Journal of medicinal chemistry.

[51]  P. Huppke,et al.  Suppression of Nonsense Mutations in Rett Syndrome by Aminoglycoside Antibiotics , 2009, Pediatric Research.

[52]  M. Bashyam.  Nonsense-mediated decay: linking a basic cellular process to human disease , 2009, Expert review of molecular diagnostics.

[53]  D. Bedwell,et al.  Poly-l-aspartic Acid Enhances and Prolongs Gentamicin-mediated Suppression of the CFTR-G542X Mutation in a Cystic Fibrosis Mouse Model* , 2009, Journal of Biological Chemistry.

[54]  Melissa J. Moore,et al.  Pre-mRNA Processing Reaches Back toTranscription and Ahead to Translation , 2009, Cell.

[55]  H. Houlden,et al.  A novel Frabin (FGD4) nonsense mutation p.R275X associated with phenotypic variability in CMT4H , 2009, Neurology.

[56]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[57]  Olga Anczuków,et al.  Comparison of nonsense-mediated mRNA decay efficiency in various murine tissues , 2008, BMC Genetics.

[58]  S. Booth,et al.  A miRNA Signature of Prion Induced Neurodegeneration , 2008, PloS one.

[59]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[60]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[61]  O. Mühlemann,et al.  Recognition and elimination of nonsense mRNA. , 2008, Biochimica et biophysica acta.

[62]  Matthew Mort,et al.  A meta‐analysis of nonsense mutations causing human genetic disease , 2008, Human mutation.

[63]  D. Geschwind,et al.  Heterogeneous dysregulation of microRNAs across the autism spectrum , 2008, neurogenetics.

[64]  P. Corn,et al.  Hypoxic regulation of mRNA expression , 2008, Cell cycle.

[65]  L. Maquat,et al.  Upf1 Phosphorylation Triggers Translational Repression during Nonsense-Mediated mRNA Decay , 2008, Cell.

[66]  Lawrence B. Gardner.  Hypoxic Inhibition of Nonsense-Mediated RNA Decay Regulates Gene Expression and the Integrated Stress Response , 2008, Molecular and Cellular Biology.

[67]  Jacqueline T Tan,et al.  Competency for nonsense-mediated reduction in collagen X mRNA is specified by the 3' UTR and corresponds to the position of mutations in Schmid metaphyseal chondrodysplasia. , 2008, American journal of human genetics.

[68]  H. Zentgraf,et al.  Incomplete nonsense-mediated decay of mutant lamin A/C mRNA provokes dilated cardiomyopathy and ventricular tachycardia , 2008, Journal of Molecular Medicine.

[69]  S. Peltz,et al.  PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model , 2008, Proceedings of the National Academy of Sciences.

[70]  J. Rousset,et al.  Drug‐induced readthrough of premature stop codons leads to the stabilization of laminin α2 chain mRNA in CMD myotubes , 2008, The journal of gene medicine.

[71]  T. Desmettre,et al.  COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. , 2007, The New England journal of medicine.

[72]  J. Lupski,et al.  Translation of SOX10 3' untranslated region causes a complex severe neurocristopathy by generation of a deleterious functional domain. , 2007, Human molecular genetics.

[73]  A. Wilkie,et al.  Nonsense‐mediated decay and the molecular pathogenesis of mutations in SALL1 and GLI3 , 2007, American journal of medical genetics. Part A.

[74]  Roy Parker,et al.  RNA Quality Control in Eukaryotes , 2007, Cell.

[75]  S. Sommer,et al.  A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin , 2007, Proceedings of the National Academy of Sciences.

[76]  J. Tazi,et al.  Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies , 2007, The Journal of cell biology.

[77]  M Claustres,et al.  Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. , 2007, American journal of human genetics.

[78]  J. Gécz,et al.  Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation , 2007, Nature Genetics.

[79]  G. Hannon,et al.  A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons , 2007, Science.

[80]  Z. Ahmed,et al.  In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome , 2007, Human Genetics.

[81]  B. Kerem,et al.  The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells , 2007, European Journal of Human Genetics.

[82]  U. Suter,et al.  Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4. , 2007, American journal of human genetics.

[83]  M. Hentze,et al.  The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the Nonsense Mediated Decay pathway , 2007, Nucleic acids research.

[84]  D. Cane,et al.  The nonsense-mediated decay RNA surveillance pathway. , 2007, Annual review of biochemistry.

[85]  J. Clancy,et al.  Restoration of W1282X CFTR activity by enhanced expression. , 2007, American journal of respiratory cell and molecular biology.

[86]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[87]  M. Wilkinson,et al.  An alternative branch of the nonsense‐mediated decay pathway , 2007, The EMBO journal.

[88]  B. Kerem,et al.  Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. , 2007, The Journal of clinical investigation.

[89]  W. Lukiw,et al.  Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus , 2007, Neuroreport.

[90]  T. Baasov,et al.  Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. , 2006, Bioorganic & medicinal chemistry letters.

[91]  C. Simone,et al.  A homozygous frameshift mutation in the ESCO2 gene: Evidence of intertissue and interindividual variation in Nmd efficiency , 2006, Journal of cellular physiology.

[92]  A. Yamashita,et al.  Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibroblasts. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[93]  D. Brooks,et al.  Stop-codon read-through for patients affected by a lysosomal storage disorder. , 2006, Trends in molecular medicine.

[94]  David Tollervey,et al.  RNA-quality control by the exosome , 2006, Nature Reviews Molecular Cell Biology.

[95]  J. Lupski,et al.  Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease , 2006, European Journal of Human Genetics.

[96]  D. Bedwell,et al.  Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model , 2006, Journal of Molecular Medicine.

[97]  G. Dreyfuss,et al.  Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. , 2006, Genes & development.

[98]  J. Leggo,et al.  Aminoglycoside suppression of nonsense mutations in severe hemophilia. , 2005, Blood.

[99]  Jingchun Sun,et al.  Relationships Among Stop Codon Usage Bias, Its Context, Isochores, and Gene Expression Level in Various Eukaryotes , 2005, Journal of Molecular Evolution.

[100]  V. Petruzzella,et al.  Mutations in the NDUFS4 gene of mitochondrial complex I alter stability of the splice variants , 2005, FEBS letters.

[101]  L. Maquat,et al.  Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. , 2005, Current opinion in cell biology.

[102]  C. Lorson,et al.  A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. , 2005, Human molecular genetics.

[103]  E. Zackai,et al.  Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations. , 2005, American journal of human genetics.

[104]  M. Wilkinson.  A new function for nonsense-mediated mRNA-decay factors. , 2005, Trends in genetics : TIG.

[105]  Luc DesGroseillers,et al.  Mammalian Staufen1 Recruits Upf1 to Specific mRNA 3′UTRs so as to Elicit mRNA Decay , 2005, Cell.

[106]  R. Gatti,et al.  Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[107]  Francisco Martinez-Murillo,et al.  Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise , 2004, Nature Genetics.

[108]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[109]  M. Hentze,et al.  Nonsense-mediated decay approaches the clinic , 2004, Nature Genetics.

[110]  P. D. de Jong,et al.  Does autosomal dominant pseudoxanthoma elasticum exist? , 2004, American journal of medical genetics. Part A.

[111]  P. Byers,et al.  Rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway. , 2004, American journal of human genetics.

[112]  D. Sillence,et al.  alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. , 2004, Journal of molecular biology.

[113]  J. Rousset,et al.  Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment , 2004, Gene Therapy.

[114]  B. Lévy,et al.  Absence of Dystrophin in Mice Reduces NO-Dependent Vascular Function and Vascular Density: Total Recovery After a Treatment with the Aminoglycoside Gentamicin , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[115]  J. Lupski,et al.  Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations , 2004, Nature Genetics.

[116]  Uwe Fass,et al.  Readthrough of dystrophin stop codon mutations induced by aminoglycosides , 2004, Annals of neurology.

[117]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[118]  Isabelle Hatin,et al.  The major 5' determinant in stop codon read-through involves two adjacent adenines. , 2004, Nucleic acids research.

[119]  K. Anders,et al.  Phosphorylation of hUPF1 induces formation of mRNA surveillance complexes containing hSMG-5 and hSMG-7. , 2003, Molecular cell.

[120]  T. Nazarenus,et al.  Genetic background affects relative nonsense mRNA accumulation in wild-type and upf mutant yeast strains , 2003, Current Genetics.

[121]  R. Savarirayan,et al.  Tissue-specific RNA surveillance? Nonsense-mediated mRNA decay causes collagen X haploinsufficiency in Schmid metaphyseal chondrodysplasia cartilage. , 2003, Human molecular genetics.

[122]  M. Hayden,et al.  An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred , 2003, Annals of neurology.

[123]  D. Stoppa-Lyonnet,et al.  The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. , 2002, Human molecular genetics.

[124]  Uta Francke,et al.  Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. , 2002, American journal of human genetics.

[125]  M. Evans,et al.  Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene , 2002, Journal of Molecular Medicine.

[126]  T. Maniatis,et al.  An extensive network of coupling among gene expression machines , 2002, Nature.

[127]  M. Pusch.  Myotonia caused by mutations in the muscle chloride channel gene CLCN1 , 2002, Human mutation.

[128]  M. Hentze,et al.  The human intronless melanocortin 4-receptor gene is NMD insensitive. , 2002, Human Molecular Genetics.

[129]  D. Bedwell,et al.  Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUAand P53 cDNAs in a mammalian translation system , 2002, Journal of Molecular Medicine.

[130]  M. Strazzabosco,et al.  Correction of CFTR malfunction and stimulation of Ca2+‐activated Cl− channels restore HCO  3− secretion in cystic fibrosis bile ductular cells , 2002, Hepatology.

[131]  M. Pericak-Vance,et al.  Erratum: The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis (Nature Genetics (2001) 29 (160-165)) , 2001 .

[132]  C. Rivolta,et al.  Dominant Leber congenital amaurosis, cone‐rod degeneration, and retinitis pigmentosa caused by mutant versions of the transcription factor CRX , 2001, Human mutation.

[133]  M. Pericak-Vance,et al.  The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis , 2001, Nature Genetics.

[134]  Caroline A. Sewry,et al.  Long mutant dystrophins and variable phenotypes: evasion of nonsense-mediated decay? , 2001, Human Genetics.

[135]  J. Clancy,et al.  Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. , 2001, American journal of respiratory and critical care medicine.

[136]  J. Alonso,et al.  Spectrum of germline RB1 gene mutations in Spanish retinoblastoma patients: Phenotypic and molecular epidemiological implications , 2001, Human mutation.

[137]  J. Oldenburg,et al.  Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. , 2001, Blood.

[138]  L. Maquat,et al.  Mammalian heat shock p70 and histone H4 transcripts, which derive from naturally intronless genes, are immune to nonsense-mediated decay. , 2001, RNA.

[139]  J. Thompson,et al.  Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. , 2001, Human molecular genetics.

[140]  S. Mundlos,et al.  Distinct mutations in the receptor tyrosine kinase gene ROR2 cause brachydactyly type B. , 2000, American journal of human genetics.

[141]  K. Flanigan,et al.  Sequence specificity of aminoglycoside‐induced stop codon readthrough: Potential implications for treatment of Duchenne muscular dystrophy , 2000, Annals of neurology.

[142]  M. Swift,et al.  Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients. , 2000, American journal of medical genetics.

[143]  D. Cooper,et al.  Molecular analysis of the genotype-phenotype relationship in factor VII deficiency , 2000, Human Genetics.

[144]  H. Sweeney,et al.  Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. , 1999, The Journal of clinical investigation.

[145]  P. Ray,et al.  Duchenne/Becker muscular dystrophy: correlation of phenotype by electroretinography with sites of dystrophin mutations , 1999, Human Genetics.

[146]  J. Yates,et al.  Clinical and molecular genetics of Stickler syndrome , 1999, Journal of medical genetics.

[147]  S. Dorman,et al.  A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection , 1999, Nature Genetics.

[148]  M Krawczak,et al.  Neighboring-nucleotide effects on the rates of germ-line single-base-pair substitution in human genes. , 1998, American journal of human genetics.

[149]  L. Maquat,et al.  A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. , 1998, Trends in biochemical sciences.

[150]  J. Clancy,et al.  Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line , 1997, Nature Medicine.

[151]  W. Reardon,et al.  Elastin: genomic structure and point mutations in patients with supravalvular aortic stenosis. , 1997, Human molecular genetics.

[152]  M. Newport,et al.  Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. , 1996, The New England journal of medicine.

[153]  M. Carter,et al.  A splicing‐dependent regulatory mechanism that detects translation signals. , 1996, The EMBO journal.

[154]  M. Willing,et al.  Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. , 1996, American journal of human genetics.

[155]  J. Lupski,et al.  Clinical Phenotypes of Different MPZ (P0) Mutations May Include Charcot–Marie–Tooth Type 1B, Dejerine–Sottas, and Congenital Hypomyelination , 1996, Neuron.

[156]  D. Bedwell,et al.  Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations , 1996, Nature Medicine.

[157]  G. Abou-Alfa,et al.  A nonsense mutation in the erythrocyte band 3 gene associated with decreased mRNA accumulation in a kindred with dominant hereditary spherocytosis. , 1996, The Journal of clinical investigation.

[158]  Daniel N. Wilson,et al.  Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon. , 1995, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[159]  S. Thein,et al.  Nonsense codon mutations in the terminal exon of the beta-globin gene are not associated with a reduction in beta-mRNA accumulation: a mechanism for the phenotype of dominant beta-thalassemia. , 1994, Blood.

[160]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[161]  C. Raetz,et al.  Partial phenotypic suppression of a peroxisome-deficient animal cell mutant treated with aminoglycoside G418. , 1992, The Journal of biological chemistry.

[162]  T. L. McGee,et al.  A Null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa , 1992, Nature Genetics.

[163]  C. M. Davenport,et al.  Rhodopsin mutations in autosomal dominant retinitis pigmentosa. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[164]  J. Clegg,et al.  Molecular basis for dominantly inherited inclusion body beta-thalassemia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[165]  S. Baserga,et al.  Nonsense mutations in the human beta-globin gene affect mRNA metabolism. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[166]  D. Housman,et al.  Absence of Messenger RNA for Beta Globin Chain in β°-Thalassaemia , 1974, Nature.

[167]  D. Bedwell,et al.  The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. , 2012, Molecular genetics and metabolism.

[168]  M. Wilkinson,et al.  © 2012 Landes Bioscience. Do not distribute. A conserved microRNA/NMD regulatory circuit controls gene expression , 2012 .

[169]  Richard J Jackson,et al.  Termination and post-termination events in eukaryotic translation. , 2012, Advances in protein chemistry and structural biology.

[170]  M. Tanner,et al.  Band 3 Walton, a C-terminal deletion associated with distal renal tubular acidosis, is expressed in the red cell membrane but retained internally in kidney cells. , 2002, Blood.

[171]  D. Sleat,et al.  Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. , 2001, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[172]  D. Cooper,et al.  Molecular analysis of the genotype-phenotype relationship in factor X deficiency , 2000, Human Genetics.

[173]  H. Dietz,et al.  Nonsense-mediated mRNA decay in health and disease. , 1999, Human molecular genetics.

[174]  L. Ala‐Kokko,et al.  Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations. , 1998, American journal of human genetics.

[175]  R. Myerowitz.  Tay‐Sachs disease‐causing mutations and neutral polymorphisms in the Hex A gene , 1997, Human mutation.

[176]  D. Housman,et al.  Absence of messenger RNA for beta globin chain in beta(0) thalassaemia. , 1974, Nature.